OXFORD, UK, June 7, 2010 /PRNewswire: PharmaTelevision® today announced that it is offering pharma and biotech companies the opportunity to reach key decision makers in the financial sector. 

To celebrate their new relationship with Reuters Insider, PharmaTelevision® is offering companies an opportunity to film, host and promote their financial or corporate messages between 21-25 June 2010.

Dr Fintan Walton, Chairman of PharmaTelevision, said “When you are looking to raise funding, communication is the key to winning the deal and building your business. Our clients benefit from our targeted approach, identifying the key decision makers from a resource of over 500,000 prospects through Reuters Insider. PharmaTelevision’s Financial Report helps companies communicate their financial or corporate message – with impact.” 

Anne Vindenes Allen, Managing Director of PharmaTelevision, said “Our team of television professionals help companies create top quality productions that combine video, text and advanced web features. Add to this PharmaTelevision’s power of distribution to top decision makers, and our ability to syndicate videos to other target audiences, and you have a formulae to help our industry progress. That’s why more companies are now choosing PharmaTelevision to convey their message.”

Reuters Insider is a powerful, internet-based delivery platform that includes an innovative set of tools that are readily available from any desktop computer or even on your mobile devices. Reuters Insider also enables you to easily create and distribute your own proprietary content using little more than a standard webcam to build your brand within the global financial community in ways never before possible.

PharmaTelevision is produced by professional television industry experts using professional studios worldwide as well as its own studios in the UK.. PharmaTelevision produces Open Content as well as subscription based Premium Content.

PharmaTelevision Open Content includes the Regional Report– a programme that focuses on the key locations for pharmaceutical and biotech investment, the Financial Report – a programme focused on companies and their performance and the Business Network – a series of interviews and profiles of some of the leading companies in biotech.

PharmaTelevision Premium Content includesPharmaTelevision News – a daily news and analysis programme, PharmaTelevision News Review – a programme featuring interviews, panel discussions and analysis with leading experts and leaders in our industry and the Business Report – a programme that analyses key business and market trends in our industry.

PharmaTelevision® is a registered Trade Mark of PharmaVentures Ltd.

For further information on PharmaTelevision’s Financial Report, or to book, contact: 

Eva Martin, Account Manager, PharmaVentures Ltd. 

+44(0)1865 332 700

enquiries@pharmatelevision.com 

For more information on PharmaTelevision, contact:

Doug Cookson, Commercial Director, PharmaVentures Ltd.

+44 (0)1865 332 731. 

doug.cookson@pharmaventures.com

– ends –

Oxford, UK, May 11, 2010: PharmaTelevision® announced that as of today the groundbreaking online TV channel for the BioPharma industry, is teaming up with Reuters Insider, a new interactive on-demand video platform designed to change the way financial professionals consume and distribute news, research and information.

Reuters Insider is a powerful, internet-based delivery platform that includes an innovative set of tools that are readily available from any desktop computer or even on your mobile devices. Reuters Insider also enables you to easily create and distribute your own proprietary content using little more than a standard webcam to build your brand within the global financial community in ways never before possible.

“As a content partner with Reuters Insider, this is a match made in heaven”, said Doug Cookson, Commercial Director, PharmaVentures. “PharmaTelevision provides a unique service for the biopharmaceutical industry providing daily television news, analysis and feature interviews with industry leaders and the relationship with Reuters Insider now allows the Financial Communities around the world to have easy access to this content.”

Anne Vindenes Allen, Managing Director, PharmaTelevision added: “This exciting relationship is now providing a clear channel for the Biopharmaceutical Industry to provide insight, particularly through our Financial Reports, in an impactful manner, to potentially hundreds of thousands of critical stakeholders in the financial sector.”

PharmaTelevision is produced by professional television industry experts using professional studios worldwide as well as its own studios in the UK.. PharmaTelevision produces Open Content as well as subscription based Premium Content.

PharmaTelevision Open Content includes the Regional Report– a programme that focuses on the key locations for pharmaceutical and biotech investment, the Financial Report – a programme focused on companies and their performance and the Business Network – a series of interviews and profiles of some of the leading companies in biotech.

PharmaTelevision Premium Content includesPharmaTelevision News – a daily news and analysis programme, PharmaTelevision News Review – a programme featuring interviews, panel discussions and analysis with leading experts and leaders in our industry and the Business Report – a programme that analyses key business and market trends in our industry.

PharmaTelevision® is a registered Trade Mark of PharmaVentures Ltd. For more information contact:

Doug Cookson, Commercial Director, PharmaVentures Ltd.

+44 (0)1865 332 731. 

doug.cookson@pharmaventures.com

– ends –

London and Oxford, United Kingdom – March 15, 2010: Matrix Corporate Capital (‘Matrix’) and PharmaVentures Limited (‘PharmaVentures’) today announced the signing of a Memorandum of Understanding (‘MOU’) covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe’s dedicated healthcare investors.

The MOU joins two firms with synergistic transactional capabilities in the healthcare life sciences space: 

Matrix is a provider of a full range of corporate finance services to small and mid cap growth companies. They are able to service companies across the full corporate lifecycle, with access to financing from Series A venture finance through IPO, secondary placements and traded debt.

PharmaVentures is a leading specialist healthcare business advisory group assisting corporations in all aspects of strategic transactions, from strategy formulations to implementation. PharmaVentures has an extensive track record of successful strategic advisory mandates in the sector with over 17 years of experience and 450 assignments, for over 600 clients, in 38 countries. 

Fintan Walton, Chief Executive of PharmaVentures said ‘For our clients our alliance with Matrix will create one of Europe’s strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement.’

Malcolm Le May, Chief Executive of Matrix Corporate Capital said ‘We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures’ help, will allow us to create innovative transactions around these assets.’

Contact

 

Matrix Corporate Capital LLP

Steve Cox, Partner

+44 203 206 7000 

PharmaVentures Limited

Tibor Papp

+44 (0)1865 332700

About Matrix Group

Matrix Corporate Capital is part of Matrix Group which is a privately owned financial services business founded in 1987 other areas of expertise include Asset Management, Property, and Specialised Finance. To date Matrix has raised around £8 billion for its investment products and currently has circa £3 billion of funds under management. Matrix’s staff of over 200 are based in the West End of London at One Vine Street. Matrix Group Limited is the holding company for the following business activities.

– ends –

Oxford, United Kingdom, 19 February 2010: PharmaTelevision Ltd announced today the launch of major new services to meet the growing demand for the production and dissemination of rich media content in the pharmaceutical and biotechnology sector. The company, a subsidiary of PharmaVentures, already provides the only online television channel dedicated to the bio-pharma industry, offering daily television news, analysis and feature interviews.

The new services include PharmaTelevision Production Services that provides unique and powerful ways for companies to communicate to industry stakeholders, as well asPharmaTelevision Conference Services, which aims to better disseminate important communications from the many business partnering, logistical, and scientific conferences within the industry. A third service, PharmaTelevision Technical Services, helps pharma and biotech companies to customise and integrate content into their existing infrastructure to drive value for their internal users.

Fintan Walton, CEO, PharmaTelevision, says, ‘PharmaTelevision is now recognised as the authoritative rich media channel for our industry. We have achieved that through close cooperation between industry leaders and our team of professional television journalists and producers to deliver programming that is second to none. The launch of these new services is a natural progression for us. We can deliver not only the highest production values, but also qualified audiences through our own media platform, as well as through our syndication partners. And that is what our clients are looking for.’

Anne Vindenes Allen, Chief Operating Officer, PharmaTelevision Ltd, continues, ‘Our industry is waking up to the impact of video. And PharmaTelevision is a show case of how video should work in the new multi-media, multi-tasking, multi-access environment. We have developed our technology platform very carefully to offer a user experience that effectively turns our video platform into an intelligence tool kit. Our pharma clients are content hungry but time poor, and the technology that we have developed, that includes rich text transcription, iPhone alerting, and in-video ‘jump to chapter’ features, has been very well received by some of the very largest companies in the sector.’

PharmaTelevision’s new services are aimed at biopharma companies, as well as those offering conference and information services to the pharmaceutical sector. Ms Allen concludes, ‘We have the pharma industry knowledge, the production expertise and the technology in place. Ultimately, this gives us confidence that we can fulfil the purpose of each and every video – delivering the right message, in the right way, to the right audience’.

PharmaTelevision is produced by professional television industry experts using professional studios worldwide as well as its own studios in Oxford, England. PharmaTelevision News is a daily ‘must see’ news service broadcast worldwide. PharmaTelevision’s new services are:

PharmaTelevision Technical Services

http://www.pharmatelevision.com 

PharmaTelevision Conference Services

http://www.pharmatelevision.com

PharmaTelevision Production Services

http://www.pharmatelevision.com

– ends –

Oxford, UK – August 17 2009 – PharmaTelevision(®), the authoritative channel for the pharmaceutical, biotechnology and related industries, announced today the launch of its new service PharmaTelevision News (PTV News), the World’s first daily television news and analysis programme for the sector.

Dr Fintan Walton, CEO of PharmaVentures – the company behind PharmaTelevision – said, “By launching PTV News, we are bringing a dynamic daily programme, covering the business of healthcare. This is a significant development, especially when you need to understand the current rapid evolution and challenges faced by our industry. Company executives and those in government and academia crave up-to-the-minute and incisive analysis – in a format that is accessible and convenient to them. And that’s what PTV News is all about.”

Dr Walton continues, “PharmaTelevision has already established a reputation for authoritative programming because we understand what pharmaceutical and biotechnology companies’ executives want. Many of our viewers are C-Suite executives, and PTV News will be invaluable to them and many others in the industry and related services.”

PTV News is produced and presented by Paul Larsmon. Mr Larsmon has worked as a broadcast television journalist for 25 years, covering general news, business and politics. He has been both presenter and producer in several news broadcasters, including the major British television news company ITN. He joined PharmaTelevision as Executive Producer earlier this year and has been responsible for getting PTV News launched. Mr Larsmon said: “This has been an exciting project involving everything from commissioning a fantastic set to organising a news gathering operation. We have seen a huge amount of interest from the industry and established an excellent pool of top commentators from around the world for the programme. I’m a news man to my core, and I’m really looking forward to developing PTV News into the best of its kind in business television.”

PTV News is available on free trial for a limited time to viewers subscribing to the PharmaTelevision Premium Content package. Interested parties should contact enquiries@pharmatelevision.com, or go to the websitehttp://www.pharmatelevision.com. Dr Walton says, “PharmaTelevision already addresses the current issues and future predictions of the industry, including those of the top companies, through news, analysis, interviews, panels and discussions. Interviewees come from leading corporations such as Johnson & Johnson, Merck & Co., sanofi-aventis, GSK, MerckSerono, and Roche.”

In addition to the News, subscribers to PharmaTelevision Premium Content can access over 200 high quality interviews and panel discussions recorded since June 2006, with fresh content delivered on a regular basis. Dr Walton concludes, “Content from PTV News and other programmes from PharmaTelevision Premium Content will be shortly available through other pay-to-view outlets. Digital television has come of age – and we are delivering the programming our industry needs.”

About PharmaTelevision(®)

PharmaTelevision (http://www.pharmatelevision.com) is the groundbreaking online TV channel for the pharmaceutical and biotech sector, offering insight, featured interviews, panel discussions and company information. Since May 2006, PharmaTelevision has rapidly grown and the channel now boasts over 200 TV programmes with a truly global audience, 60% of whom are C-suite executives. PharmaTelevision’s TV programmes include Financial Report and the Regional Report, giving our viewers a complete overview of industry trends, analysis including deals, investments and strategic policies within the sector. Now in 2009, PharmaTelevision is launching PTV News – a daily summary and analysis of the major news headlines, ensuring that, wherever in the world they are, our audience can stay truly informed.

Watch the PTV News trailer.

Testimonials about the value of PharmaTelevision from industry leading figures can be viewed 

PharmaTelevision is a part of the business media division of PharmaVentures Ltd (http://www.pharmaventures.com).

– ends –

Oxford, UK – 15 July 2009 – PharmaTelevision, the authoritative channel for the pharmaceutical, biotechnology and related industries, announced today the launch of its new service, PharmaTelevision Premium Content. PTV Premium Content will include PTV News – a daily news and analysis service to be launched in August. Subscription to the service will be free until 30 September, 2009. Dr Fintan Walton, CEO of PharmaVentures – the company behind PharmaTelevision – said, “Television captures and delivers something unique, recognising that business is ultimately about the people in it – whether it’s a part of deal making, or discovery and development, or about a company’s ability to finance itself. It’s not a surprise to us that PharmaTelevision has become ‘must view’ TV for many senior executives and managers”.

Dr Walton continues, “Launch of this new service means we can deliver to our subscribers great television programming and integrated news and analysis information services.” PharmaTelevision addresses the current issues and future predictions of the industry, including those of the top companies, through news, analysis, interviews, panels and discussions. Interviewees come from companies such as Johnson & Johnson, Merck & Co., sanofi-aventis, Genzyme, MerckSerono, NICE UK, and Roche. As well as PTV News, current programmes include PharmaVentures Business Review; The Regional Report; The Financial Report; and PharmaDeals(R) Commentaries, and bring the major industry players straight to desktops – on demand from the viewer.

Dr Walton says, “This year, development to PharmaTelevision has been rapid as we meet the demand from our discerning audience. Our subscribers can look forward to significant upgrades that help them uncover further value in the service, and not least will shortly see news services compiled jointly by top experts from both the pharmaceutical and the television world. Subscribers to PharmaTelevision Premium Content can access over 200 high quality interviews and panel discussions filmed since June 2006. Dr Walton concludes, “It’s an exciting time for us and our viewers.”

About PharmaTelevision(R)

PharmaTelevision (http://www.pharmatelevision.com) is the groundbreaking online TV channel for the pharmaceutical and biotech sector, offering insight, featured interviews, panel discussions and company information. Since May 2006, PharmaTelevision has rapidly grown and the channel now boasts over 200 TV programmes with a truly global audience, 60% of whom are C-suite executives. In 2008, the channel launched a sleek new look and introduced two exciting TV programmes – the Financial Report and the Regional Report, which, together with our well-established TV programmes, help to give our viewers a complete overview of industry trends, analysis including deals, investments and strategic policies within the sector. In 2009, PharmaTelevision will be launching PTV News – a daily summary and analysis of the major news headlines, ensuring that, wherever in the world they are, our audience can stay truly informed.

Testimonials about the value of PharmaTelevision from industry leading figures can be viewed online

A promotional Video about PharmaTelevision can be viewedonline

For further information, or to receive a demonstration of the new service, please contact:

Lisa Holloway, +44 (0)1865 784 177 lisa.holloway@pharmaventures.com

PharmaTelevision is a part of the business media division of PharmaVentures Ltd (http://www.pharmaventures.com).

– ends –